NEW YORK, Feb 18 (Reuters) - Johnson & Johnson (JNJ.N), opens new tab faces a critical test on Tuesday over its $10 billion proposal to end litigation alleging that its baby powder caused ovarian ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback